Sebastian Schneeweiss, Sc.D., M.D.
This page shows the publications co-authored by Sebastian Schneeweiss and Martin Kulldorff.
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab. 2020 Jan; 3(1):e00103.
Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. Diabetes Obes Metab. 2019 08; 21(8):1824-1836.
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019 06 18; 139(25):2822-2830.
Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. Circ Cardiovasc Qual Outcomes. 2019 02; 12(2):e005173.
Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. Epidemiology. 2018 11; 29(6):895-903.
A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Endocrinol Diabetes Metab. 2021 07; 4(3):e00237.
Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.